Scroll for more

Sucampo is a global biopharmaceutical company that is built on the ongoing pursuit of scientific innovation and an unwavering passion for improving the lives of patients.

Read more about Sucampo
At Sucampo, science is at the core of everything we do. We are committed to developing our own programs and partnering with others to incorporate new scientific knowledge to help best address the pressing health needs of our patients. Learn more about our pipeline.
We have a proven track record of successful pharmaceutical product development and approvals.


Sucampo Pharmaceuticals, Inc. is a publicly traded, global biopharmaceutical company committed to scientific innovation that improves the lives of patients.
Developing strategic partnerships is a cornerstone of our business philosophy, allowing us to match our expertise with the knowledge and capabilities of others to create, access and deliver the most needed and innovative pharmaceutical treatments. Learn more about our partnership opportunities.
News & Media center
Welcome to our News & Media Center, where you can search our press releases for the latest information on Sucampo.

View additional press releases in the archive.
We value a passion for life-changing science and promote this both within our company and within the biopharmaceutical industry. We are proud to foster a team-oriented, entrepreneurial culture filled with talented people. Learn more about our career opportunities.

NASDAQ SCMP Jan 19, 2018 • 4:00 PM EST


Contact Us
Tel: +1-301-961-3400

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.